Peptides are an important class of drugs, but their potential for treating
chronic diseases will be fully realized only if more acceptable delivery
methods than daily injections can be developed. Recognition of this has led to
advances in oral, intranasal, inhaled, transdermal, and buccal formulations.
This report analyses the products and companies at the forefront of such
FEATURES AND BENEFITS
- Assess the breadth of innovations that have been applied to the delivery
of peptide drugs.
- Compare the various technologies developed for use within particular
- Evaluate the merits and limitations of each company's peptide delivery
- Gain insight from analysis of the patents filed to protect specific
- Understand the technical principles on which the delivery technologies are
The demise of Exubera, an inhaled insulin product, has had a knock-on effect
on the inhaled insulin technologies and there are now few still in
development, despite products offering strong advantages such as fast
absorption, fast onset of action, and a non-invasive mode of administration.
New oral nanotechnology peptide formulations are showing promise, particularly
in the area of insulin and GLP-1 analog delivery. New long-acting peptides and
controlled release injectable formulations are extending peptide half-lives
significantly, leading to weekly and even monthly subcutaneous injectable
First- and second-generation transdermal patch technologies were not suitable
for peptide drug delivery due to the need for low molecular weight and low
dose loading, but third-generation patch technologies (such as thermal
ablation, microneedles, vesicular carriers, and iontophoresis) are offering
promise in the delivery of several peptides.
YOUR KEY QUESTIONS ANSWERED
- What type of delivery technologies are available to those developing
- What peptide delivery challenges are the innovations intended to overcome?
- Which indications offer the greatest advances by investment in delivery
- Which companies have already formed partnerships with the inventors of
cutting-edge delivery techniques?
- What hurdles remain for specific technologies and how far are they from
being employed in a commercialized drug?